Modulation of atp production or content in the hypothalamus
OwnerDavid Macleaninventor
Life of this patent
Estimating the term…
Abstract
A method for the identification of agents for use in the treatment of metabolic diseases, disorders or conditions, for example obesity and diabetes, or for causing weight loss without substantial adverse health effects, in an animal in need of such treatment, comprises the step of identifying an agent that modulates ATP production or content in the hypothalamus of an animal.
Claims60
A method for the identification of agents for use in the treatment of metabolic diseases, disorders or conditions in an animal in need of such treatment, comprising the step of identifying an agent that modulates ATP production or content in the hypothalamus of the animal.
A method comprising the step of identifying an agent that modulates ATP production or content in the hypothalamus of the animal, wherein said method identified agents that:
- a. regulate food-intake or calorific-intake in the animal, or
- b. decrease food-intake or calorific-intake in an animal, or
- c. cause body mass reduction in an animal without substantial adverse health effects, or
- d. aid in the treatment of diabetes in an animal in need of such treatment.
(canceled)
(canceled)
A method for the identification of agents for use in the treatment of diabetes in an animal in need of such treatment, comprising the step of identifying an agent that modulates ATP production or content in the hypothalamus of the animal.
(canceled)
A method for treating a metabolic disease, disorder or condition in an animal in need of such treatment, comprising administering a therapeutically effective amount of an agent known through scientific research to modulate ATP production or content in the hypothalamus of the animal, and for the purpose of knowingly modulating ATP production or content in the hypothalamus of the animal.
A pharmaceutical composition comprising a therapeutically effective amount of an agent known through scientific research to modulate ATP production or content in the hypothalamus of an animal, wherein said composition is a-medicament for treating a metabolic disease, disorder or condition in the animal in need of such treatment by knowingly modulating ATP production or content in the hypothalamus of the animal.
(canceled)
(canceled)
(canceled)
(canceled)
A method for causing body mass reduction in an animal without substantial adverse health effects, comprising administering a therapeutically effective amount of an agent known through scientific research to modulate ATP production or content in the hypothalamus of the animal, and for the purpose of knowingly modulating ATP production or content in the hypothalamus of the animal.
A pharmaceutical composition comprising a therapeutically effective amount of an agent known through scientific research to modulate ATP production or content in the hypothalamus of an animal, wherein said composition is a medicament for causing body mass reduction in the animal without substantial adverse health effects by knowingly modulating ATP production or content in the hypothalamus of the animal.
A substance adapted for administration to an animal and intended to treat metabolic diseases, disorders and conditions in the animal or to cause weight loss in the animal without substantial adverse health effects, the substance comprising a therapeutically effective amount of an agent known through scientific research to modulate the production or content of ATP in the hypothalamus of the animal, optionally in association with a pharmaceutically acceptable or dietetic excipient, diluent or carrier, or a foodstuff or beverage.
A method for the identification of agents for use in the treatment of appetitive diseases, disorders, or conditions in an animal comprising the step of identifying an agent that modulates ATP production in the hypothalamus of said animal.
A method for the identification of agents that regulate food-intake in an animal comprising the step of identifying an agent that modulates ATP production in the hypothalamus of said animal.
A method for the identification of agents for use in the treatment of diabetes in an animal comprising the step of identifying an agent that increases ATP production or content in the hypothalamus of said animal.
A method for treating an appetitive disease, disorder, or condition comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of an agent that modulates ATP production in the hypothalamus of an animal, provided that said agent is not an extract from a plant of the genus Trichocaulon or Hoodia.
(canceled)
A method for treating diabetes comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of an agent that increases ATP production or content in the hypothalamus of an animal, provided that said agent is not an extract from a plant of the genus Trichocaulon or Hoodia.
A pharmaceutical composition comprising therapeutically effective amount of an agent that modulates ATP production in the hypothalamus of an animal, wherein the composition is a medicament for treating an appetitive disease, disorder, or condition in an animal in need of such treatment, provided that said agent is not an extract from a plant of the genus Trichocaulon or Hoodia.
(canceled)
A pharmaceutical composition comprising therapeutically effective amount of an agent that increases ATP production or content in the hypothalamus of an animal, wherein the composition is a medicament for treating diabetes in an animal in need of such treatment, provided that said agent is not an extract from a plant of the genus Trichocaulon or Hoodia.
Dependencies are inferred from the claim text.